从移植患者的肺部中氨酶系统受体的定位和表达:一个病例对照研究
Andresa Thomé Silveira1,2, Lucas Sagrillo Fagundes1,3, Juliane Flor1,2
1Laboratório de Fisiologia Translacional, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 91501-970, RS, Brazil.
Biomedicines
|September 27, 2025
概括
异形性肺纤维化 (IPF) 患者在肺组织中表现出-血管素系统 (RAS) 受体表达的改变,AT1和Mas受体增加. 这些发现表明,组织特异性的RAS活性可能为IPF提供新的治疗点.
科学领域:
- 肺部医学 肺部医学
- 心血管研究研究心血管研究
- 分子生物学分子生物学
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺病,治疗选择有限.
- 胺-血管素系统 (RAS) 在心血管和功能中发挥作用,但其在肺组织中的作用,特别是在IPF中,尚未完全理解.
研究的目的:
- 研究IPF患者肺组织中关键RAS受体 (AT1,Mas,MrgD) 的表达和定位.
- 在IPF患者和对照者之间比较与RAS相关的血度.
- 为了将肺受体表达与临床参数如肺功能和依赖氧气等相关联.
主要方法:
- 病例控制研究涉及19名接受肺部手术或移植的IPF患者.
- 使用液体染色学-并联质谱法测量等离子体 (Angiotensin I, II, A, 1-7, Alamandine) 的数量.
- 评价肺组织受体表达 (AT1,Mas,MrgD) 通过西斑和免疫组织化学.
主要成果:
- IPF患者的肺功能显著降低 (FVC,FEV1) 和增加氧气依赖.
- 血水平在很大程度上是相似的,在对照组中Angiotensin I水平较高.
- IPF肺组织显示血管素1型 (AT1) 和Mas受体的表达增加,并减少了MrgD表达.
- 马斯受体局部存在于支气管中,而MrgD则主要存在于肺膜内.
结论:
- 胺-血管素系统 (RAS) 在肺部表现出明显的组织特异性活动,与其全身功能分开.
- 在IPF肺部Mas和MrgD受体的改变表达和定位表明它们可能参与疾病的发病.
- 在肺组织中准这些特定的RAS受体可能是IPF的新治疗策略.
相关概念视频
01:28Kidney Transplant I: Introduction
343
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
343
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K